modulator of VRAC current 1Genealiases: LVM · MLC · VL
Q-omics provides the consensus-scored MLC1 profile across patient tissues and cancer cell-line models. MLC1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MLC1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MLC1 RNA expression shows 13,200 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, KIRC, and TGCT as cancer lineages where MLC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MLC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MLC1 survival associations across molecular data types. MLC1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MLC1 RNA expression–survival associations across cancer types. High MLC1 expression shows favorable associations in CESC, HNSC, LIHC, UCS, READ and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MLC1 RNA expression.
This table summarizes MLC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MLC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MLC1 shows lower tumor expression in LUAD, LUSC, PRAD, UCEC and BLCA and higher tumor expression in KIRC. The KIRC box plot shows higher MLC1 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with MLC1 in patient tissues and cancer cell lines. In patient samples, MLC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MLC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
